Literature DB >> 11416040

Quantitative analysis of estrogen receptor proteins in rat mammary gland.

S Saji1, H Sakaguchi, S Andersson, M Warner, J Gustafsson .   

Abstract

Estrogen receptor alpha and beta proteins (ERalpha and ERbeta) at various stages of development of the rat mammary gland were quantified by Western blotting. ERalpha and ERbeta recombinant proteins were used as standards, and their molar concentrations were measured by ligand binding assays. In 3-week-old pregnant, lactating, and postlactating rats the ERalpha content ranged from 0.30-1.55 fmol/microg total protein (mean values). The ERbeta content of the same samples ranged between 1.06-7.50 fmol/microg total protein. At every developmental stage, the ERbeta content of the mammary gland was higher than that of ERalpha. When receptor levels were normalized against beta-actin, it was evident that ER expression changed during development, with maximum expression of both receptors during the lactation period. With an antibody raised against the 18-amino acid insert of the ERbeta variant, originally called ERbeta2 but named ERbetains in this paper, Western blots revealed that ERbetains protein was up-regulated during the lactation period. RT-PCR showed that the levels of messenger RNA of ERbetains paralleled those of the protein. Double immunohistochemical staining with anti-ERalpha and anti-ERbetains antibodies revealed that ERbetains protein colocalized with ERalpha in 70-80% of the ERalpha-expressing epithelial cells during lactation and with 30% of these cells during pregnancy. These observations indicate that expression of ERbetains is regulated not only quantitatively, but also with regard to its cellular distribution. As ERbetains acts as the dominant repressor of ERalpha, we suggest that its coexpression with ERalpha quenches ERalpha function and may be one of the factors that contribute to the previously described insensitivity of the mammary gland to estrogens during lactation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11416040     DOI: 10.1210/endo.142.7.8260

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.

Authors:  Amy M Fowler; Szeman Ruby Chan; Terry L Sharp; Nicole M Fettig; Dong Zhou; Carmen S Dence; Kathryn E Carlson; M Jeyakumar; John A Katzenellenbogen; Robert D Schreiber; Michael J Welch
Journal:  J Nucl Med       Date:  2012-06-05       Impact factor: 10.057

2.  Expression of estrogen and progesterone receptors in the bovine ovary during estrous cycle and pregnancy.

Authors:  Bajram Berisha; Michael W Pfaffl; Dieter Schams
Journal:  Endocrine       Date:  2002-04       Impact factor: 3.633

3.  Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.

Authors:  Shyam N Sundar; Crystal N Marconett; Victor B Doan; Jamin A Willoughby; Gary L Firestone
Journal:  Carcinogenesis       Date:  2008-09-10       Impact factor: 4.944

4.  Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas.

Authors:  Vilde D Haakensen; Trine Bjøro; Torben Lüders; Margit Riis; Ida K Bukholm; Vessela N Kristensen; Melissa A Troester; Marit M Homen; Giske Ursin; Anne-Lise Børresen-Dale; Åslaug Helland
Journal:  BMC Cancer       Date:  2011-08-03       Impact factor: 4.430

Review 5.  Sex hormone receptor repertoire in breast cancer.

Authors:  Gerald M Higa; Ryan G Fell
Journal:  Int J Breast Cancer       Date:  2013-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.